BACE1 and Alzheimer disease: It is well-documented that oxidative stress and the expression of cholinesterases and BACE-1 play a vital role in AD initiation and progression [3,4,17]; thus, an ideal AD therapeutic agent should function against different AD pathogenic mechanisms [23].